| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Autoimmune encephalopathy
Autoimmune encephalopathy
is increasingly recognized
Many cases of encephalopathy previously considered infectious are now recognized to have an autoimmune cause. In fact, based on a recent Mayo Clinic study, autoimmune encephalitis was found to be as common as infectious encephalitis.1
KLHL11
Learn more about the world’s first evidence-based test to confirm the presence of Kelch-like protein 11 (KLHL11) autoantibodies.
Ma2-directed illness
Mayo Clinic Laboratories has optimized detection of Ma2-associated autoimmune encephalitis through development of an innovative, enzyme-linked immunosorbent assay.
When to consider testing
Consider autoimmune testing for patients presenting with new-onset encephalopathy (non-infectious or metabolic) and one or more of the following:
Key testing
Phenotypic evaluations
Our autoimmune encephalopathy evaluation is part of an evolving approach to testing for autoimmune neurological disorders using phenotypic-specific evaluations that include multiple antibodies known for their disease association.
Beyond the Test Result
Greg Widseth was suddenly hit by a rare disease that prompted his immune system to attack his brain cells, resulting in as many as 60 seizures a day. Special blood and spinal fluid tests developed by Mayo Clinic Laboratories confirmed that Widseth had antibodies known to target certain brain cells.
Articles and resources
